john lilley

Mr. john lilley

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
FSFinbar Slevin
Finbar Slevin
KAKatharine L. Aitken
Katharine L. Aitken
Filippo AlongiFilippo Alongi
Filippo Alongi
SASTEFANO ARCANGELI
STEFANO ARCANGELI
ECEliot Chadwick
Eliot Chadwick
LMLouise Murray
Louise Murray


1 June 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
ACAnanya Choudhury
Ananya Choudhury
STStelios Theophanous
Stelios Theophanous
PLPer-Ivar Lønne
Per-Ivar Lønne
RSRobert Samuel
Robert Samuel
MGMarianne Grønlie Guren
Marianne Grønlie Guren
AAAne Appelt
Ane Appelt

28 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
CTChristopher Thompson
Christopher Thompson
CPChristopher Pagett
Christopher Pagett
JLjohn lilley
john lilley
SSStina Svensson
Stina Svensson
KEKjell Eriksson
Kjell Eriksson
AAAne Appelt
Ane Appelt
(1) Background: The STRIDeR (Support Tool for Re-Irradiation Decisions guided by Radiobiology) planning pathway aims to facilitate anatomically appropriate and radiobiologically meaningful re-irradiation (reRT). This work evaluated the STRIDeR pathway for robustness compared to a more conservative manual pathway. (2) Methods: For ten high-grade glioma reRT patient cases, uncertainties were applied and cumulative doses re-summed. Geometric uncertainties of 3, 6 and 9 mm were applied to the background dose, and LQ model robustness was tested using α/β variations (values 1, 2 and 5 Gy) and the linear quadratic linear (LQL) model δ variations (values 0.1 and 0.2). STRIDeR robust optimised plans, incorporating the geometric and α/β uncertainties during optimisation, were also generated. (3) Results: The STRIDeR and manual pathways both achieved clinically acceptable plans in 8/10 cases but with statistically significant improvements in the PTV D98% (p < 0.01) for STRIDeR. Geometric and LQ robustness tests showed comparable robustness within both pathways. STRIDeR plans generated to incorporate uncertainties during optimisation resulted in a superior plan robustness with a minimal impact on PTV dose benefits. (4) Conclusions: Our results indicate that STRIDeR pathway plans achieved a similar robustness to manual pathways with improved PTV doses. Geometric and LQ model uncertainties can be incorporated into the STRIDeR pathway to facilitate robust optimisation.

26 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
FSFinbar Slevin
Finbar Slevin
SASophie Alexander
Sophie Alexander
SBSarah R Brown
Sarah R Brown
MCMatthew Carter
Matthew Carter
ACAnanya Choudhury
Ananya Choudhury
AHAnn M Henry
Ann M Henry
Introduction Prostate cancer (PCa) is the most common cancer in men. Recurrence may occur in up to half of patients initially treated with curative intent for high-risk localised/locally advanced PCa. Pelvic nodal recurrence is common in this setting, but no clear standard of care exists for these patients, with potential therapeutic approaches including stereotactic body radiotherapy (SBRT) to the involved node(s) alone, extended nodal irradiation (ENI) to treat sites of potential micrometastatic spread in addition to involved node(s) and androgen deprivation therapy with or without additional systemic anticancer therapies. Based on observational studies, ENI is associated with promising metastasis-free survival (MFS) compared with SBRT and appears to result in low rates of severe late toxicity. Methods and analysis Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer is a UK multicentre, open-label, phase III randomised controlled trial, which will deliver much needed, high-quality evidence of the impact on metastatic progression from ENI compared with SBRT in patients with PCa pelvic nodal recurrence. The trial will also evaluate the long-term toxicity of 5-fraction ENI compared with a standard 20-fraction schedule. The trail will randomise 480 participants in a ratio of 2:1:1 to SBRT, 5-fraction ENI or 20-fraction ENI from 35 to 40 UK radiotherapy sites over 4 years. Coprimary endpoints are MFS at 3 years and participant-reported late bowel toxicity at 3 years. Secondary endpoints include overall survival, biochemical progression-free survival, failure-free survival, patterns of failure, participant-reported/clinician-reported toxicity and health-related quality of life. Collection of blood and tissue samples will enable future evaluation of biomarkers of disease and toxicity and support stratification of salvage therapeutic approaches. Ethics and dissemination Ethical approval was obtained from NHS Health Research Authority, East of England – Cambridgeshire and Hertfordshire Research Ethics Committee (24/EE/0099). Trial results will be published in peer-reviewed journals and adhere to International Committee of Medical Journal Editors guidelines. Trial registration number ISRCTN11089334, registered on 23 September 2024.

23 January 2023 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Closed access
BEBehnaz Elhaminia
Behnaz Elhaminia
AGAlexandra Gilbert
Alexandra Gilbert
JLjohn lilley
john lilley
MAMoloud Abdar
Moloud Abdar
Attilio FrangiAttilio Frangi
Attilio Frangi
AGAli Gooya
Ali Gooya
Modern radiotherapy delivers treatment plans optimised on an individual patient level, using CT-based 3D models of patient anatomy. This optimisation is fundamentally based on simple assumptions about the relationship between radiation dose delivered to the cancer (increased dose will increase cancer control) and normal tissue (increased dose will increase rate of side effects). The details of these relationships are still not well understood, especially for radiation-induced toxicity. We propose a convolutional neural network based on multiple instance learning to analyse toxicity relationships for patients receiving pelvic radiotherapy. A dataset comprising of 315 patients were included in this study; with 3D dose distributions, pre-treatment CT scans with annotated abdominal structures, and patient-reported toxicity scores provided for each participant. In addition, we propose a novel mechanism for segregating the attentions over space and dose/imaging features independently for a better understanding of the anatomical distribution of toxicity. Quantitative and qualitative experiments were performed to evaluate the network performance. The proposed network could predict toxicity with 80% accuracy. Attention analysis over space demonstrated that there was a significant association between radiation dose to the anterior and right iliac of the abdomen and patient-reported toxicity. Experimental results showed that the proposed network had outstanding performance for toxicity prediction, localisation and explanation with the ability of generalisation for an unseen dataset.